Announcement • Oct 20
Oaktree Acquisition Corp. III Life Sciences Appoints David A. Berry as an Independent Director, Audit Committee, Nominating Committee and Compensation Committee On October 17, 2025, the board of directors of Oaktree Acquisition Corp. III Life Sciences appointed David A. Berry, MD, PhD, as an independent director of the Company. Dr. Berry will serve as a Class II director until his successor is duly appointed and qualified or until his earlier resignation, removal or other cessation as a director. Dr. Berry was also appointed to serve on the Board’s audit committee, nominating committee and compensation committee. Dr. Berry is co-founder of Averin Capital, where he has been serving as a Managing Partner since May 2025. Previously, Dr. Berry served as a Partner from 2008 to 2015, and as a General Partner from 2015 to May 2025, at Flagship Pioneering, where he has worked since November 2005. Dr. Berry was previously founder and CEO of Valo Health where he served on the board from October 2018 through January 2024. He served on the board of directors of Omega Therapeutics Inc. (Nasdaq: OMGA) from August 2017 to June 2022. He also served as a director of Seres Therapeutics Inc. (Nasdaq: MCRB) from September 2012 to July 2016, and served as its CEO from 2012 to 2014. Dr. Berry also served as the Chief Executive Officer and as a member of the board of directors of Axcella Health Inc. (Nasdaq: AXLA) from September 2009 until May 2020, and as Chief Executive Officer and as a member of the board of Evelo Biosciences (Nasdaq: EVLO) from May 2014 to February 2018. He holds an M.D. from Harvard Medical School, a Ph.D. in biological engineering from the Massachusetts Institute of Technology and a B.S. in brain and cognitive sciences from the Massachusetts Institute of Technology. Announcement • Jan 08
Oaktree Acquisition Corp. Iii Life Sciences Announces Board Changes Oaktree Acquisition Corp. III Life Sciences announced On January 6, 2025, John Frank resigned from the board of directors. In connection with Mr. Frank’s resignation, the Board appointed (i) Aman Kumar, currently a director of the Company, as the new chairman of the Board, and (ii) Zaid Pardesi, the Company’s Chief Executive Officer, as a director of the Company. Mr. Pardesi will serve on the Board as a Class III director whose term will expire at the Company’s third annual meeting of shareholders. Mr. Frank’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. 
